Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.58 |
| ▸ | NPC1 | O15118 | 10/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.58 |
| ▸ | MEN1 | O00255 | 8/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 10/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12593856 | 0.87 | NPC1 (0.52) | MAPTNPC1KDM4EMEN1KMT2A | |
| SCHEMBL12428710 | 0.87 | HSD17B1 (0.51) | MAPTNPC1KDM4EMEN1KMT2A | |
| SCHEMBL1747973 | 0.85 | NPC1 (0.56) | MAPTNPC1KDM4EMEN1KMT2A | |
| SCHEMBL1747917 | 0.85 | DYRK1A (0.51) | MAPTNPC1KDM4EMEN1KMT2A | |
| SCHEMBL1748255 | 0.84 | NPC1 (0.60) | MAPTNPC1KDM4EMEN1KMT2A | |
| SCHEMBL1748356 | 0.84 | RAB9A (0.47) | MAPTNPC1KDM4EMEN1KMT2A | |
| SCHEMBL1748062 | 0.82 | DGAT1 (0.55) | MAPTNPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL1761517 | 0.82 | MAPT (0.74) | MAPTNPC1KDM4EMEN1KMT2A | |
| SCHEMBL1748331 | 0.80 | DYRK1A (0.41) | MAPTNPC1KDM4EMEN1KMT2A | |
| SCHEMBL1748216 | 0.77 | DYRK1A (0.51) | MAPTNPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013056679-A1 | NOVEL HETEROARYL-AMINO DERIVATIVES | BEIJING HANMI PHARMACEUTICAL CO., LTD (CN) | 2013-04-25 | — | — | WO | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| CN-101087769-A | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2007-12-12 | — | — | CN | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1805156-A2 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| CN-1816531-A | Process for the preparation of aryl alkyl acid derivatives and their use for the treatment of obesity | BAYER PHARMACEUTICALS CORP (US) | 2006-08-09 | — | — | CN | disclosed |
| WO-2006044775-A2 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, PGC | MAPT 3560/4885NPC1 466/4885KDM4E 278/4885 |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | MAPT 4379/4885NPC1 187/4885KDM4E 817/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | MAPT 4379/4885NPC1 187/4885KDM4E 817/4885 |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, PGC | MAPT 3560/4885NPC1 466/4885KDM4E 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.